Ignite Creation Date:
2025-12-26 @ 11:47 AM
Ignite Modification Date:
2025-12-26 @ 11:47 AM
Study NCT ID:
NCT00289016
Status:
COMPLETED
Last Update Posted:
2015-12-18
First Post:
2006-02-08
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
Sponsor:
BioVex Limited
Organization:
Study Overview
Official Title:
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: